New Perioperative Strategies Emerge for High-Risk, Resectable RCC
December 4th 2019
The current management of metastatic renal cell carcinoma reflects the progress of medical oncology throughout the past several decades. The standard of care has evolved from cytokine-based therapies to targeted molecular therapies and immune checkpoint inhibitor–based strategies.